Clinicalpharmacological study of 0.0015% DE-085 (tafluprost) ophthalmic solution in healthy adult male volunteers. -ocular blood flow measurements as efficacy endpoints
Phase 1
- Conditions
- Glaucoma
- Registration Number
- JPRN-UMIN000000518
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Brief Summary
It can be suggested that 0.0015% DE-085 ophthalmic solution and 0.01% bunazosin hydrochloride ophthalmic solution (one drop at a time, single administration) increase the blood flow in human retinal and retinal artery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) Any clinically abnormal findings at screening examinations.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1) Peripapillary retinal and neuroretinal rim hemodynamics (2) Peripapillary retinal artery hemodynamics
- Secondary Outcome Measures
Name Time Method